<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>7 Oesophageal tumours</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part12.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part14.htm">Далее &gt;</a></p><p style="padding-top: 3pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="#bookmark12" class="s95" name="bookmark45">Chapter 7</a><a name="bookmark46">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 55pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_113.png"/></span></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><h2 href="#bookmark12">Oesophageal tumours</h2></p><p class="s5" style="padding-top: 10pt;padding-left: 53pt;text-indent: 0pt;text-align: left;">Kieran Foley, Carys Morgan, and Tom Crosby</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-top: 13pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">7.1 <span class="h4">Clinical background</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Oesophageal cancer is the eighth most common cancer in the UK, with &gt;9000 new cases diagnosed per year. The prognosis is poor, with overall five-year survival rates of approximately 15%. The incidence varies widely around the world, ranging from 5 to 10 per 100,000 in developed countries to 100 per 100,000 in endemic areas. Overall, squamous cell carcinoma (SCC) is more common (5.2 per 100,000) than adeno- carcinoma (0.7 per 100,000). SCC is most common in south-east and central Asian countries such as Turkey, Iran, and Northern China (79% of total cases worldwide). Adenocarcinoma is more common in developed countries in northern and western Europe, North America, and Australasia (46% of total cases).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">7.2 <span class="h4">Diagnosis and staging</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">7.2.1 <span class="s29">Diagnosis</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Oesophageal cancer is most commonly diagnosed following upper gastrointestinal (GI) endoscopy. Endoscopy is the first-line investigation and enables direct visual- ization of the tumour and biopsy for histological diagnosis. The length, location, and degree of obstruction of the visible tumour (measured from the incisors or from the oesophagogastric junction (OGJ)) can be assessed. Contrast studies remain a useful alternative investigation in patients with dysphagia, but far fewer studies are per- formed now compared to computed tomography (CT) (Figure 7.1). Benign lesions are common and include strictures related to previous surgery, gastro-oesophageal reflux, long-term use of a nasogastric tube, chemical injury, and treatment of oesophageal varices. An advantage of contrast swallow over endoscopy is the detection of motility disorders such as achalasia.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">7.2.2 <span class="s29">Staging</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The accepted standard for staging of oesophageal and OGJ cancers is based on the Union of International Cancer Control (UICC) Tumour Node Metastasis (TNM) sta- ging system, currently in its eighth edition (Table 7.1). Accurate staging is required to determine prognosis and management options, such as curative versus palliative intent and single versus multimodality treatment.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 52pt;text-indent: 0pt;text-align: left;">	</p><p style="text-indent: 0pt;text-align: left;"><span><img width="148" height="212" alt="image" src="Image_114.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="150" height="211" alt="image" src="Image_115.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 7.1 <span class="s52">Contrast swallow showing (a) an adenocarcinoma of lower third of oesophagus and (b) a small adenocarcinoma at the oesophagogastric junction.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 11pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">After a diagnosis of oesophageal cancer, patients are initially staged with CT of the chest and abdomen. This is predominately to assess the primary tumour for poten- tial resectability (loco-regional stage) and to identify distant metastases (commonly liver, lungs, peritoneum, and non-regional lymph nodes). Potentially curable patients who are fit for radical treatment, either with surgery, chemotherapy, radiotherapy, or a combination, should undergo 18-fluorine (<span class="s22">18</span>F) fluorodeoxyglucose (FDG) PET/CT followed by endoscopic ultrasound (EUS) for more detailed staging. MRI is occasion- ally performed in some countries. Invasive EUS-guided fine needle aspiration (EUS- FNA) is also an important diagnostic tool and can help confirm diagnosis and stage, thereby assisting clinical treatment decisions.</p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">7.2.2.1 <span class="s98">T stage</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">There is a strong correlation between the depth of tumour invasion and risk of lymph node metastases in oesophageal cancer. This in turn correlates with risk of distant me- tastases and a worsening five-year survival. Although CT does not accurately differ- entiate the anatomical layers of the oesophageal wall to predict T stage, it can identify invasion of adjacent structures such as aorta, vertebral body, pericardium, lungs, and bronchus in patients with locally advanced disease. Fat planes usually separate the oesophagus from adjacent organs. The presence of a visible fat plane can accurately predict absence of invasion into an adjacent organ. However, loss of the fat plane does not necessarily mean that invasion has occurred. The likelihood of irresectability can also be assessed by measuring the extent of tumour surrounding the aorta. If the de- gree of encasement is &gt;180º, vascular invasion is likely and if &gt;270º, invasion is almost inevitable, both features negating the possibility of surgical resection. However, loss of fat plane between tumour and pericardium is less predictive of invasion, and fat planes can be obscured following radiotherapy.</p><p class="s24" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Table 7.1 <span class="s52">TnM eighth edition of oesophageal cancer staging</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:11.3387pt" cellspacing="0"><tr style="height:14pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">T primary tumour</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">TX</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">primary tumour cannot be assessed</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T0</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">no evidence of primary tumour</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Tis</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Carcinoma <i>in situ</i>/high-grade dysplasia</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T1</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Tumour invades the lamina propria, muscularis mucosae, or submucosa</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T1a</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Tumour invades the lamina propria or muscularis mucosae</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T1b</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Tumour invades the submucosa</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T2</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Tumour invades muscularis propria</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T3</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Tumour invades adventitia</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T4</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Tumour invades adjacent structures</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T4a</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Tumour invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T4b</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Tumour invades other adjacent structures, such as the aorta, vertebral body, or trachea</p></td></tr><tr style="height:15pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">N regional lymph nodes</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">nX</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">lymph node status cannot be assessed</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n0</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">no regional lymph node metastasis</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n1</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Metastasis in 1–2 regional lymph nodes</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n2</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Metastasis in 3–6 regional lymph nodes</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n3</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Metastasis in 7 or more regional lymph nodes</p></td></tr><tr style="height:15pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M distant metastasis</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M0</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">no distant metastasis</p></td></tr><tr style="height:15pt"><td style="width:19pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M1</p></td><td style="width:304pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Distant metastasis</p></td></tr></table><p class="s14" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;line-height: 109%;text-align: left;">reproduced with permission from sobin lh, gospodarowicz MK, Wittekind Ch. <i>UICC TNM Classification of Malignant Tumours</i>. 8th ed. © 2017 Wiley Blackwell.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Transoesophageal EUS combines upper GI endoscopy with ultrasonography (US) using a dedicated US probe. The five layers of the oesophageal wall can be clearly visualized, each with different echogenic appearance. The first layer corresponds to the superficial mucosa, the second layer to the muscularis mucosa, the third layer to the submucosa, the fourth layer to the muscularis propria, and the fifth layer to the adventitia. Therefore, EUS can accurately predict the depth of tumour invasion. Multiple studies using EUS have consistently reported an overall T stage accuracy of</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">&gt;80% compared to surgical pathology, and this improves with increasing T stage to</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">&gt;90% with T3/T4 tumours (Figure 7.2). Meta-analysis of 27 studies demonstrated an accuracy of 89% for EUS T staging. The additional use of EUS staging information can influence the patient’s management in approximately 25% of cases. However, there are limitations of EUS. First, distinguishing mucosal (Tis or T1a) from submucosal lesions (T1b) in early tumours is difficult. The primary tumour will be understaged</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="223" height="170" alt="image" src="Image_116.png"/></span></p><p class="s70" style="padding-top: 5pt;padding-left: 64pt;text-indent: 0pt;text-align: left;">Aorta</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s70" style="padding-left: 65pt;text-indent: 0pt;text-align: left;">Node</p><p class="s70" style="padding-top: 2pt;padding-left: 261pt;text-indent: 0pt;text-align: left;">Tumour</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s70" style="padding-left: 44pt;text-indent: 0pt;text-align: left;">Left atrium</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 7.2 <span class="s52">endoscopic ultrasound image of a T3n1 tumour.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">in 5% and overstaged in 6–11%. Second, it has been reported that around 30% of tu- mours are non-traversable; however, failure rates as low as 3% have been published using narrow-calibre, blind endoscopes. Third, EUS is operator dependent with a long learning curve of experience and careful audit, as accurate assessment is based on size, shape, margins, and echotexture.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The use of FDG-PET to detect oesophageal tumours is reported to be more sensi- tive than CT, for both SCC and adenocarcinoma. Combined analysis of seven studies (with a total of 281 patients) using FDG-PET as part of initial staging, showed that the site of primary tumour could be correctly identified in 94%. In the 5% of tumours not identified, small size (&lt;5 mm) was the main reason for false negative results. Also, a small subset of tumours do not take up FDG, irrespective of size. These are usu- ally adenocarcinomas, either mucin-producing, poorly differentiated, or signet-ring subtype. Occasionally, an incidental finding of a small tumour arising within a hiatus hernia or segment of Barrett’s oesophagus can be seen on a PET/CT examination performed for a different indication. In patients already known to have oesophageal cancer, FDG-PET does not add any further T stage information compared to CT. False positive FDG-PET uptake in the oesophagus can occur with inflammatory disease, gastro-oesophageal reflux, or radiation-induced oesophagitis, often appearing as dif- fuse rather than focal uptake, confirming the need for histological diagnosis.</p><p class="s97" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">7.2.2.2 <span class="s98">N stage</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The oesophagus has a rich lymphatic network within the submucosa. Even early T stage tumours are at significant risk of lymph node metastases. This risk ranges from 3–6% for mucosal (T1a) to 21–24% for submucosal (T1b) tumours, 45–75% for intramuscular tumours, and 80–85% for transmural tumours. N stage refers to in- volvement of regional lymph nodes, defined as those within a peri-oesophageal distri- bution. Non-regional lymph nodes, including supra-clavicular and coeliac axis nodes, are classified as distant metastases (M1). Accurate identification of lymph node me- tastases as coeliac axis (M1 disease) rather than left gastric is critical because it can change the patient management from potentially curative to palliative. The presence of lymph node metastases is a major prognostic indicator.</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The number, size, and location of lymph nodes relative to the tumour can be dem- onstrated on CT, with nodes &gt;10 mm in short-axis diameter considered more likely to be involved. However, enlarged nodes are seen in non-malignant processes such as reactive hyperplasia or inflammation. Conversely, involved nodes may not appear enlarged on CT. Therefore, the sensitivity and specificity of CT for detecting involved lymph nodes is poor (31–44%). In general, all modalities are likely to under-stage nodal disease.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">EUS provides better assessment of regional nodes. Several studies have compared EUS with CT and FDG-PET. In a study of patients undergoing surgical resection, Flamen et al. reported that EUS was more sensitive than FDG-PET (81% vs. 33%) but less specific (67% vs. 89%). The combined results of CT with EUS did not alter the cumulative specificity over FDG-PET, indicating that nodal detection alone fails to differentiate benign from malignant disease.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">One meta-analysis found the sensitivity of CT, EUS, and PET/CT for the detection of regional lymph node metastases was 50%, 80%, and 57%, respectively. The specifi- city was 83%, 70%, and 85%, respectively, suggesting EUS is better than CT or PET for excluding regional lymph node metastases. The study also found the sensitivity and specificity of diagnosing coeliac lymph node metastases with EUS was 85% and 96%, respectively.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Another meta-analysis of 12 studies (including 490 patients) using FDG-PET to stage regional lymph nodes reported an overall sensitivity of 51% and specificity of 84%. A similar meta-analysis including six studies demonstrated that the pooled sen- sitivity and specificity of PET/CT was 55% and 76%, respectively. There are two main reasons for the poor sensitivity of PET in detecting involved regional lymph nodes. First, FDG uptake by small volume metastases within involved nodes may be insuf- ficient for detection. Second, despite detectable FDG uptake in involved nodes, the limited spatial resolution of PET cannot differentiate peri-tumoural nodes from the adjacent primary tumour.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The use of EUS-guided fine needle aspiration (EUS-FNA) enables histological con- firmation of lymph node involvement within the diagnostic work-up and improves the sensitivity from 85% to &gt;95%.<span class="s22">1 </span>EUS-FNA of gastric and coeliac axis nodes can also be performed to stage non-regional lymph nodes. This procedure has been incorpor- ated into the standard protocol for investigating potential surgical candidates in some centres, particularly when there is uncertainty about involvement of a node that would change management.</p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">7.2.2.3 <span class="s98">M stage</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The risk of distant metastases increases with the T stage. At presentation, 20–30% of patients with oesophageal cancer have distant metastases. The major additional contri- bution of FDG-PET in oesophageal cancer is the superior detection of distant metas- tases that are not identified by CT. Small occult metastases in the liver and bone may be undetectable on CT and common incidental lesions in the thyroid gland, skeletal muscle, and pancreas are often interpreted as benign.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The sensitivity and specificity of CT and PET/CT is 52% and 91%, and 71% and 93%, respectively. Similarly, a meta-analysis showed a pooled sensitivity and</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">specificity of 67% and 97%, respectively. Importantly, PET/CT can change man- agement in up to 38% of patients, with most cases changing because of upstaging. However, in 5% of patients, lesions measuring &lt;1 cm (particularly in the liver or lung) may not be detected by PET/CT. Whole body imaging with PET/CT has also contributed to the detection of synchronous primary tumours, most often in the head and neck, and colon, while false positive findings are seen in inflammatory disorders such as sarcoidosis.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">7.3 <span class="h4">Imaging for radiotherapy planning</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The use of radiotherapy in oesophageal cancer can either be for curative or pallia- tive intent. In the curative setting, radiotherapy is often used in combination with chemotherapy (known as chemo-radiotherapy (CRT)) either definitively or as part of a multimodality approach with surgery. This is usually preoperative (neo-adjuvant) or less commonly postoperative (adjuvant).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">For radiotherapy planning, a CT is performed with intravenous contrast to im- prove definition of mediastinal anatomy (Figure 7.3). The planning CT includes the lung apices down to the iliac crest, ensuring full coverage of organs at risk. There is significant movement, particularly in the lower oesophagus and OGJ due to re- spiratory and cardiac motion, and level of gastric distension. Reproducible stomach filling can be attempted to allow for this movement during treatment and ensure full coverage of disease.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="417" height="275" alt="image" src="Image_117.jpg"/></span></p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 7.3 <span class="s52">a contrast enhanced computed tomography volume modulated arc therapy (VMaT) radical radiotherapy plan with multi-planar reconstructions and organs at risk outlined.</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">There is increasing use of four-dimensional CT (4DCT) radiotherapy planning. This technique incorporates organ motion seen particularly during respiration. A 4DCT acquires and reconstructs the data at different time points throughout the respira- tory cycle. During the CT, the respiratory cycle is tracked in real-time and divided into ‘bins’ of respiratory phase. After scanning, the images are sorted into phases, from which several CT datasets (usually 8–10) are reconstructed at the different time points. This process tracks tumour and surrounding organ motion and ensures tu- mour coverage throughout the respiratory cycle.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Oesophageal tumours are difficult to define on planning CT alone so all diagnostic information including endoscopy, diagnostic CT, EUS, and <span class="s22">18</span>F-FDG PET/CT should be available during gross tumour volume (GTV) delineation. Visible disease on any imaging modality should be included, otherwise the disease extent may be underesti- mated. Submucosal tumour extension, skip lesions, and involved lymph nodes can be found at significant distances beyond the visible tumour. This is more likely to be detected by EUS than CT. In addition, PET/CT alone may underestimate the length of primary disease and should be used in combination with EUS where possible. As dis- cussed previously, EUS may also define local nodal disease more accurately and should therefore be considered in patients undergoing radical radiotherapy to accurately de- fine disease extent. EUS measurements of the superior and inferior limits of disease need to be related to a reproducible anatomical landmark in the thorax. A suitable reference point is the top of the arch of the aorta or the carina.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">7.4 <span class="h4">Therapeutic assessment and follow-up</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Following completion of treatment, the risk of recurrence remains high and usually occurs within the first two years. Recurrent disease is associated with a poor prog- nosis. The current primary modality to assess treatment response and detect recurrent disease is CT, although the role of <span class="s22">18</span>F-FDG PET/CT to detect disease recurrence is emerging. A limitation of CT is the difficulty in reliably differentiating post-treatment changes from recurrent or residual disease. In patients receiving neo-adjuvant treat- ment, an early response detectable on PET/CT may predict for long-term outcome but this is not currently standard of care. Post-treatment CT can be difficult to interpret and additional endoscopic assessment is recommended in those patients where sur- gical salvage is a potential option.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">7.4.1 <span class="s29">Assessing response to therapy</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The treatment options for oesophageal cancer include surgical and non-surgical ap- proaches. The addition of neo-adjuvant CRT prior to resection improves survival when compared with surgery alone. Patients who respond well to neo-adjuvant CRT and achieve a pathological complete response (pCR) may not benefit from surgical resection. Reported pCR rates range from 8% to 56% (mean 24%) following preopera- tive CRT and resection. As patients are unlikely to benefit from surgical resection, the ability to predict pCR would contribute significantly to the patient’s management and reduce treatment morbidity.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="358" height="172" alt="image" src="Image_118.gif"/></span></p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="358" height="191" alt="image" src="Image_119.gif"/></span></p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s52" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;"><span class="s24">Fig. 7.4 </span>a 70-year-old woman with a T3 n0 M0 squamous cell carcinoma of the lower oesophagus. pre-treatment <span class="s102">18</span>F-FDg peT, fused peT/CT, and Mip images</p><p class="s52" style="padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: left;">(a) show a tumour with an suV<span class="s103">max </span>of 14.9. FDg uptake in brown fat in the supraclavicular fossae is a normal variant. images four months later (b) following</p><p class="s52" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: left;">neoadjuvant CrT show a 50% reduction in tumour suV<span class="s103">max</span>. note FDg-uptake in the right adjacent lung margin due to radiotherapy.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 8pt;line-height: 12pt;text-align: justify;">Currently, a combination of modalities is relied upon to assess response. CT is relatively inaccurate for determining tumour and lymph node response, with studies showing little correlation between reduction in tumour size and pathological response. Although EUS is a good tool for preoperative staging, its utility is limited for assessing response, as it cannot differentiate residual tumour from post-treatment fibrosis. Metabolic imaging with <span class="s22">18</span>F-FDG PET can be used to assess response to therapy (Figure 7.4). A baseline scan is required to compare with subsequent scans and the degree of FDG uptake within the tumour objectively measured using the maximum standard uptake value (SUV<span class="s36">max</span>). Studies have shown that a reduction in SUV<span class="s36">max </span>at 14 days after commencement of pre- operative chemotherapy or CRT correlates with good histological tumour regression and improved survival. However, one study assessing FDG uptake after seven days failed to demonstrate this correlation, possibly due to the short interval allowing insufficient metabolic response to occur.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 18pt;text-indent: 0pt;text-align: left;">	</p><p style="text-indent: 0pt;text-align: left;"><span><img width="199" height="181" alt="image" src="Image_120.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="205" height="182" alt="image" src="Image_121.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s52" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 114%;text-align: left;"><span class="s24">Fig. 7.5 </span>(a) a 63-year-old man with T3 n0 M0 adenocarcinoma of the lower oesophagus on baseline fused <span class="s102">18</span>F-FDg peT/CT and peT images. (b) Following a complete response to neoadjuvant CrT and subsequent surgery, new liver metastases indicate distant disease recurrence.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Ongoing studies are also assessing how this information from early <span class="s22">18</span>F-FDG PET/ CT can potentially be used to change or intensify treatment in non-responders. The MUNICON studies assessed use of FDG-PET to assess response to preoperative chemotherapy, In the initial trial, ‘metabolic responders’ were associated with improved outcomes. The MUNICON II trial looked at the addition of radiation to the treatment regime in metabolic ‘non-responders’. The results of these studies confirmed that early PET-CT can differentiate patients with better outcomes but radiation did not improve survival in non-responders in this trial. Further studies in this area are ongoing.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">7.4.2 <span class="s29">Follow-up</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The role of regular CT imaging in the follow-up of asymptomatic patients who have completed curative treatment is unproven as recurrent disease is rarely salvaged suc- cessfully. <span class="s22">18</span>F-FDG PET/CT may detect recurrent loco-regional or distant metastatic disease (Figure 7.5). However, like CT, this is not used routinely in the follow-up of asymptomatic patients. False positive findings at the anastomotic site or in adjacent mediastinal lymph nodes can occur due to inflammation.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">7.5 <span class="h4">Summary</span></p><p class="s23" style="padding-top: 6pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">A combination of imaging modalities is required to improve oesophageal cancer staging accuracy.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Lymph node metastases are an important prognostic indicator but diagnostic ac- curacy remains relatively poor.</span></p><p style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;"><span class="s23">◆ </span>Diagnostic CT should be used to identify patients with unresectable primary tu- mours or distant metastases before proceeding to <span class="s22">18</span>F-FDG PET/CT and EUS.</p><p class="s23" style="padding-top: 4pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="s65">18</span><span class="s44">F-FDG PET/CT is an important modality in oesophageal cancer staging by increasing the sensitivity of distant metastasis detection and changing patient management.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">The use of PET/CT to assess early treatment response and potentially guide treat- ment is an area of interest and active research.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s73" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Further reading</p><p class="s74" style="padding-top: 5pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Flamen P</b>, <b>Lerut A</b>, <b>Van Cutsem E, et al. </b>(2000). Utility of positron emission tomography for the staging of patients with potentially operable oesophageal carcinoma. <i>Journal of Clinical Oncology</i>, <b>18</b>: 3202–3210.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: justify;"><b>Foley KG</b>, <b>Christian A</b>, <b>Fielding P</b>, <b>Lewis WG</b>, <b>Roberts SA </b>(2017). Accuracy of contemporary oesophageal cancer lymph node staging with radiological-pathological correlation. <i>Clinical Radiology</i>, <b>72</b>(8): e691–e697.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Kayani B</b>, <b>Zacharakis E</b>, <b>Ahmed K</b>, <b>Hanna GB </b>(2011). Lymph node metastases and prognosis in oesophageal carcinoma-a systematic review. <i>European Journal of Surgical Oncology</i>, <b>37</b>(9): 747–753.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Lordick F</b>, <b>Ott K</b>, <b>Krause BJ, et al. </b>(2007). PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. <i>Lancet Oncology</i>, <b>8</b>: 797–805.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Monjazeb AM</b>, <b>Riedlinger G</b>, <b>Aklilu M, et al. </b>(2010). Outcomes of patients with esophageal cancer staged with 18F-fluorodeoxyglucose positron emission tomography (FDG- PET): can postchemoradiotherapy FDG-PET predict the utility of resection? <i>Journal of Clinical Oncology</i>, <b>28</b>: 4714–4721.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Ott K</b>, <b>Wolfgang A</b>, <b>Lordick F, et al. </b>(2006). Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophogastric junction. <i>Journal of Clinical Oncology</i>, <b>24</b>: 4692–4698.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: justify;"><b>Puli SR</b>, <b>Reddy JB</b>, <b>Bechtold ML, et al. </b>(2008). Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. <i>World Journal of Gastroenterology</i>, <b>14</b>: 1479–1490.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Sobin LH</b>, <b>Gospodarowicz MK</b>, <b>Wittekind CH (2017)</b>. <i>UICC TNM Classification of Malignant Tumours </i>(eighth edn). Chichester: Wiley Blackwell.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>van Hagen P</b>, <b>Hulshof MCCM</b>, <b>van Lanschot JJB, et al. </b>(2012). Preoperative chemoradiotherapy for esophageal or junctional cancer. <i>New England Journal of Medicine</i>, <b>366</b>: 2074–2084.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s73" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Reference</p><p class="s74" style="padding-top: 5pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">1. <b>van Vliet EP</b>, <b>Heijenbrok-Kal MH</b>, <b>Hunink MG</b>, <b>Kuipers EJ</b>, <b>Siersema PD </b>(2008). Staging investigations for oesophageal cancer: a meta-analysis. <i>British Journal of Cancer</i>, <b>98</b>(3): 547–557.</p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part12.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part14.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
